Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evalua...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
SAGE Publishing
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/31934071c47149bf87053edf3807d5a3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!